ANT1 is reduced in sporadic inclusion body myositis

Neurological Sciences

Volumn 34, Issue 2, 2013, Pages 217-224

  Barca, E ^a   Aguennouz, M ^a   Mazzeo, A ^a   Messina, S ^a   Toscano, A ^a   Vita, Gian Luca ^a   Portaro, S ^a   Parisi, D ^a   Rodolico, C ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

ANT1; Apoptosis; NF B; PM; sIBM

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCATOR PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOCHONDRIAL PROTEIN; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INCLUSION BODY MYOSITIS; MALE; MUSCLE TISSUE; PATHOGENESIS; POLYMYOSITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE SECTION; WESTERN BLOTTING;

EID: 84879687919     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-012-0976-2     Document Type: Article

References (39)

1. Briani C, Doria A, Sarzi-Puttini P, Dalakas MC (2006) Update on idiopathic inflammatory myopathies. Autoimmunity 39:161-170
2. Ballo P, Chiodi L, Cameli M, Malandrini A, Federico A, Mondillo S, Zuppiroli A (2011) Dilated cardiomyopathy and inclusion body myositis. Neurol Sci Sep 16
3. Sancricca C, Mora M, Ricci E, Tonali PA, Mantegazza R, Mirabella M (2011) Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci 32(5):841-847
4. Murata KY, Kouda K, Tajima F, Kondo T (2011) A dysphagia study in patients with sporadic inclusion body myositis (s-IBM). Neurol Sci
5. Needham M, Mastaglia FL (2008) Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Disord 18:6-16
6. Vattemi G, Engel WK, McFerrin J, Askanas V (2004) Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol 164:1-7
7. Wojcik S, Engel WK, Yan R, McFerrin J, Askanas V (2007) NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in AβPP-overexpressing cultured human muscle fibers. Acta Neuropathol 114:517-526
8. Santorelli FM, Sciacco M, Tanji K et al (1996) Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: a study of 56 patients. Ann Neurol 39:789-795
9. Oldfors A, Moslemi AR, Jonasson L, Ohlsson M, Kollberg G, Lindberg C (2006) Mitochondrial abnormalities in inclusion-body myositis. Neurology 66:S49-S55
10. Nogalska A, Wojcik S, Engel WK, McFerrin J, Askanas V (2007) Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol 204:610-618
11. Vattemi G, Engel WK, McFerrin J, Pastorino L, Buxbaum JD, Askanas V (2003) BACE1 and BACE2 in pathologic and normal human muscle. Exp Neurol 179:150-158
12. Askanas V, Engel WK (2006) Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 66:S39-S48
13. Arahata K, Engel A (1988) Monoclonal antibody analysis of mononuclear cells in myopathies: identification and quantification of T8+ cytotoxic and T8+ suppressor cells. Ann Neurol 23:493-499
14. Schneider C, Gold R, Dalakas MC et al (1996) MHC class I-mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropathol Exp Neurol 55:1205-1209
15. Silverman N, Maniatis T (2001) NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev 15:2321-2342
16. Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621-663
17. Zhang G, Ghosh S (2001) Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 107:13-19
18. Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725-734
19. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310
20. Fagiolari G, Sciacco M, Chiveri L et al (2002) Lack of apoptosis in patients with progressive external ophthalmoplegia and mutated adenine nucleotide translocator-1 gene. Muscle Nerve 26:265-269
21. Esposito LA, Melov S, Panov A, Cottrell BA, Wallace DC (1999) Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci USA 96(9):4820-4825
22. Vander Heiden MG, Chandel NS, Schumacker PT, Thompson CB (1999) Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Mol Cell 3:159-167
23. Zamora M, Meroño C, Viñas O, Mampel T (2004) Recruitment of NF-kappaB into mitochondria is involved in adenine nucleotide translocase 1 (ANT1)-induced apoptosis. J Biol Chem 279:38415-38423
24. Askanas V, Engel WK, Alvarez RB (1993) Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology 43:1265-1267
25. Zeviani M, Moraes CT, DiMauro S, Nakase H, Bonilla E, Schon EA, Rowland LP (1998) Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 51(6):1525-1532
26. Askanas V, Alvarez RB, Mirabella M, Engel WK (1996) Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Ann Neurol 39:389-391
27. Macaione V, Aguennouz M, Rodolico C et al (2007) RAGE-NF-kappaB pathway activation in response to oxidative stress in facioscapulohumeral muscular dystrophy. Acta Neurol Scand 115:115-121
28. Monici MC, Aguennouz M, Mazzeo A, Messina C, Vita G (2003) Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 60:993-997
29. Yang CC, Askanas V, Engel WK, Alvarez RB (1998) Immunolocalization of transcription factor NF-kappaB in inclusion-body myositis muscle and at normal human neuromuscular junctions. Neurosci Lett 254:77-80
30. Schmitz ML, Mattioli I, Buss H, Kracht M (2004) NF-kappaB: a multifaceted transcription factor regulated at several levels. Chembiochem 5:1348-1358
31. Askanas V, Engel WK (2005) Molecular pathology and pathogenesis of inclusion-body myositis. Microsc Res Tech 67:114-120
32. Barkett M, Gilmore TD (1999) Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18:6910-6924
33. Delhalle S, Deregowski V, Benoit V, Merville MP, Bours V (2002) NF-kappaB-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis. Oncogene 21:3917-3924
34. Lodi R, Taylor DJ, Tabrizi SJ et al (1998) Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy. Brain 121:2119-2126
35. Zoratti M, Szabò I (1995) The mitochondrial permeability transition. Biochim Biophys Acta 1241:139-176
36. Leung AW, Halestrap AP (2008) Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim Biophys Acta 1777:946-952
37. Behrens L, Bender A, Johnson MA, Hohlfeld R (1997) Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 120:929-938
38. Fyhr IM, Lindberg C, Oldfors A (2002) Expression of Bcl-2 in inclusion body myositis. Acta Neurol Scand 105:403-407
39. Belzacq AS, Vieira HL, Verrier F et al (2003) Bcl-2 and Bax modulate adenine nucleotide translocase activity. Cancer Res 63:541-546